<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sample of skin substitutes, indication for use, and study data&lt;SUP&gt;[1]&lt;/SUP&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sample of skin substitutes, indication for use, and study data<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Sample of skin substitutes, indication for use, and study data<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="15%"></colgroup><colgroup span="3" width="25%"></colgroup><colgroup width="10%"></colgroup> <tbody> <tr> <td class="subtitle1">Matrix</td> <td class="subtitle1">Source</td> <td class="subtitle1">Indication</td> <td class="subtitle1">Study outcome</td> <td class="subtitle1">Level of evidence</td> </tr> <tr class="divider_bottom"> <td>BLCC </td> <td> <p><strong>Dermal part:</strong> bovine type I collagen with human neonatal foreskin fibroblasts.</p> <strong>Epidermal part:</strong> keratinocytes. </td> <td>VLUs, DFUs, PG, burns, acute wounds, epidermolysis bullosa, post-radiation ulcers</td> <td> <p><strong>In VLUs:</strong> 63% of patients were healed at 6 months compared with 49% (using standard of care). Also, higher likelihood to achieve complete wound closure by 6 months than the control group.</p> <strong>In DFUs:</strong> Closure in 56% of patients by 12 weeks compared with 39% of patients with conventional therapy. </td> <td>Level I<sup>[2,3]</sup></td> </tr> <tr class="divider_bottom"> <td>DHACM </td> <td>DHACM is composed of a single layer of epithelial cells, a basement membrane, and an avascular connective tissue matrix.</td> <td>DFUs, VLUs, chronic vascular ulcers, partial- and full- thickness wounds, PUs, surgical wounds, trauma wounds, and burns</td> <td> <p><strong>In DFUs:</strong> 97% of patients treated with DHACM achieved wound closure by 12 weeks compared with 51% with standard wound care.</p> <strong>In VLUs:</strong> 62% of patients treated with DHACM plus compression therapy showed wound closure at 4 weeks compared with only 32% with compression therapy alone. </td> <td>Level II<sup>[4,5]</sup></td> </tr> <tr class="divider_bottom"> <td>DRM </td> <td>Composed of a cross-linked bovine collagen and glycosaminoglycan dermal layer, and a silicone epidermal layer.</td> <td>Partial- and full-thickness wounds, PUs, VLUs, DFUs, surgical wounds, burns, and draining wounds</td> <td> <p>The combination of DRM with postoperative negative-pressure therapy versus DRM alone increased the take rate from 78% to 98%.</p> <p>The interval between DRM and skin transplantation was decreased from 24 to 10 days and can decrease length of hospital stay.</p> <strong>In DFUs:</strong> 51% of patients achieved complete closure with DRM compared with 32% of the control group. 43 days to closure versus 78 days. </td> <td>Level I and II<sup>[6,7]</sup></td> </tr> <tr> <td>CA </td> <td>Cadaveric human skin that has been processed to remove the epidermis.</td> <td>Indicated in the repair of damaged or inadequate integument including surgical wounds from abdominal wall reconstruction and breast reconstruction</td> <td>86% of patients receiving CA were closed by 16 weeks compared with only 29% of control patients (diabetic lower extremity wounds).</td> <td>Level II<sup>[8]</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes">BLCC: bilayered living cell construct; VLU: venous leg ulcer; DFU: diabetic foot ulcer; PG: pyoderma gangrenosum; DHACM: dehydrated human amnion/chorion membrane; DRM: dermal replacement matrix; PU: pressure ulcer; RTM: Regenerative Tissue Matrix; CA: cadaveric allograft.</div><div class="graphic_reference">References:

<ol>
<li>Shahrokhi S, Arno A, Jeschke MG. The use of dermal substitutes in burn surgery: Acute phase. Wound Repair Regen 2014; 22:14.</li>
<li>Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: A prospective randomized multicenter clinical trial. Diabetes Care 2001; 24:290.</li>
<li>Kirsner RS, Sabolinski ML, Parsons NB, et al. Comparative effectiveness of a bioengineered living cellular construct vs. a dehydrated human amniotic membrane allograft for the treatment of diabetic foot ulcers in a real world setting. Wound Repair Regen 2015; 23:737.</li>
<li>Serena TE, Carter MJ, Le LT, et al. A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. Wound Repair Regen 2014; 22:688.</li>
<li>Zelen CM, Serena TE, Gould L, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: A prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J 2016; 13:272.</li>
<li>Driver VR, Lavery LA, Reyzelman AM, et al. A clinical trial of Integra Template for diabetic foot ulcer treatment. Wound Repair Regen 2015; 23:891.</li>
<li>Jeschke MG, Rose C, Angele P, et al. Development of new reconstructive techniques: Use of Integra in combination with fibrin glue and negative-pressure therapy for reconstruction of acute and chronic wounds. Plast Reconstr Surg 2004; 113:525.</li>
<li>Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: A prospective 16-week pilot study. Int Wound J 2006; 3:181.</li>
</ol>

Adapted from: Hughes OB, Rakosi A, Macquhae F, et al. A review of cellular and acellular matrix products: Indications, techniques, and outcomes. Plast Reconstr Surg 2016; 138:138S.</div><div id="graphicVersion">Graphic 118083 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
